Salubris Refiles For Hong Kong IPO As Generics Lose Steam
The producer of cardiovascular drugs is accelerating its shift towards innovative pharmaceuticals, under pressure from price cuts and expiring patents image credit: Bamboo Works Key Takeaways: Salubris
A drug company is trying to go public in Hong Kong and is moving away from older cheap medicines toward new invented drugs because old medicines make less money now. When a company changes its main business like this, watch to see if their new products work out or if the switch costs them too much.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.